CA1341014C - Hcg peptides for use in antibody purification procedures - Google Patents

Abstract

An affinity column antibody purification method using a synthetic hCG analyte-analog insolubilized on a support material. The immobilized hCG analyte-analogs are peptide sequences which duplicate or mimic the determinants formed by the amino acid residues of the C-terminus peptide sequence or portions or variants thereof. The antibodies produced according to the present invention are useful in immunoassays for hCG.

Description

hCG PEPTIDES FOR USE IN ANTIBODY PURIFICATION PROCEDURES
REFERENCE TO RELATED APPLICATION
c.
BACKIaROUND OF THE INVENTION
1 Ci 1 . Field of the Invention This invention relates to antibody purification techniques. In particular, the invention relates to synthetic human chorionic gonadotropin (hCG) peptides for the purification of polyclonal anti-hCG antibodies.
1 :i 2. Description of Related Various analytical procedures and devices are commonly employed in assays to determine the presence and/or concentration of substances of interest or clinical significance which may be present in biological fluids or other materials.
Such substances are commonly termed "aralytes" and can include antibodies, antigens, drugs, hormones, etc.

2 () The detection of particular analytes in biological fluids such as serum, plasma, urine, spinal fluid and the like has in recent years become of critical importance in both research and clinical settings. The detection of analyzes of interest can often be related to various disease states and consequently is. extremely useful in the diagnosis of disease and in monitoring the effectiveness of therapy. When the analytes are antigens or antibodies, 2 > assays typically depend upon the immunological reactivity which characterizes these substances. Generally, such assays are collectively termed immunoassays.
Immunoassay techniques take advantage of the mechanisms of the immune systems of higher organisms, wherein antiboclies are produced in response to the presence of antigens which are pathogenic or f~~reign to the organisms. One or more antibodies are produced in 3 0 response to and are cap~3ble of reacting with a particular antigen, thereby creating a highly specific reaction mechanism which can be used in vitro to determine the presence or concentration of that antil~en in a biological sample.
The results of an immunoassay, however, can vary according to the type of antibody used and the antibody's specificity for the particular antigen. In a quantitative assay for 3 Ei hCG, the particular anti-hCG antibody used may cross-react with a second glycoprotein antigen, such as human leutenizing hormone (hLH), follicle stimulating hormone (FSH) or thyroid stimulating hormone (TSH), thereby decreasing the accuracy of the assay. For example, an antibody that recognizes and binds with hCG generally will also bind to LH, FSH
and TSH rather than specifically binding with hCG. Antibody purification methods have been devised to minimize cross-reactivity. Typical of such conventional methodologies is one which uses a two column technique involving a first affinity column containing a whole molecule hCG to concentrate a specific group of IgG molecules, and a second affinity column containing LH or FSH in an attempt to remove antibodies that cross-react with hCG. The hCG
polyclonal antibodies obtained from this conventional procedure still have significant cross-reactivity. In addition, the two column technique is a time consuming and expensive procedure.
1 0 Chemical analysis of analytes, such as hCG and hLH, has shown that the cross-reactivity of these tyormon~a is duF; to trieir a-subunits which are structurally similar.
Therefore, attempts have been made to separate arid purify the fi-subunit of hCG (fi-hCG) which is comparatively distinct in structure from hLH. The separation procedures, however, can still result in the occurrence of impurities and the inclusion of amino acid 1 5 sequences common to both hCG and hLH.
The peptide moiety situated at the COOH terminus of 13-hCG consists of about amino acids. It was found that this moiety permits a distinct identification of hCG versus hLH (Matsuura et al, Endocrinology 104: 396, 1979). Iwasa et al, describe the production of a synthetic peptide sequence which reproduces a specific portion of the COOH terminal 2 0 peptide (CTP) of f3-hCG for use in the preparation of an anti-hCG antibody (U.S. Patent 4,517,290). The amino acid sequence of the CTP of f3-hCG consists of 45 amino acids, as follows:
Gly-Gly-Pro-Lys-Asp105_His.-Pro-Leu-Thr-Cys110_Asp-Asp-Pro-Arg-Phe115-25 Gln-Asp-Ser-Ser-Ser120_Se~r-Lys-Ala-Pro-Pro125_Pro-Ser-Leu-Pro-Ser130-Pro-Ser-Arg-Leu-Pro135_Gly-Pro-Ser-Asp-Thr140-Pro-Ile-Leu-Pro-Gln 1 45 as described by Morgan et at, Mol.. Cell. Biochem. 2(1 ), 97-99 (1973). The synthetic peptide sequence described by Iwas;a for polyclonal antibody purification comprises CTP
3 0 fragments or subsequences of from 10 to 23 amino acid residues, such as:
Gly-Pro-Ser-Asp-Thr140_Pro-Ile-Leu-Pro-GIn145 with increased sequence lengths up to Ala-Pro-Pro125_Pro-Ser-Le~u-Pro-Ser130_pro-Ser-Arg-Leu-Pro135_ Gly-Pro-Ser-Asp-Thr140-Pro-Ile-Leu-Pra-GIn145.
None of the art described above discloses or suggests the use of CTP sequences greater than 23 amino acid residues in size to alleviate the cross-reactivity characteristics of antibodies.
SUMNIARY OF THE INVENTION
It has now been discovered, and the present invention is based upon this discovery, that particular synthetic amino acid sequences can be advantageously used to produce highly specific anti-hCG antibodies. Accordingly, the present invention is directed to a method for purifying an anti-hCG antibody usingi hCG analyte-analogs and to the production of the hCG
1 5 analyte-analogs. The purification method involves an affinity column containing an hCG
analyte-analog insolubilized on a carrier or support, wherein the hCG analyte-analog has the following peptide sequence:
Asp112-Pro-Arg-PhEa115-Gln-Asp-Ser-Ser-Ser120_Ser-Lys-Ala-Pro-Pro125_ Pro-Ser-Leu-Pro-Ser130-Pro-Ser-Arg-Leu-Pro135_Gly-Pro-Ser-Asp-Thr140-Pro-Ile-Leu-Pro-GIn145 Those anti-hCG antibodies having an epitope in common with the peptide sequence are specifically absorbed from a fluid a~ntaining anti-hCG antibodies.
2 5 Other suitable hCG analyte-2malog peptide sequences of the present invention include variants of the C-terminus peptide such as:
Asx 1 1 2_ Pro-Arg-Phe~ 1 1 5_Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro1 25_ Ser-Leu-Pro-Ser-Pro130-SE~r-Arg-Leu-Pro-GIy135_pro-Pro-Asx-Thr-Pro140_ 3 0 Ile-Leu-Pro-Glx-Serf 45-Leu-Pro.
wherein Asx can be Asp or Asn and Glx can be Gln or Glu. Further suitable peptide sequences of the present invention can also include one or more terminal Lys residues to facilitate the immobilization of the peptide upon the support for use in the affinity column.
For example, 3 5 the hCG analyte-analog peplide sequence can comprise:

~~41014 Asx> > 2-Pro-Arg-Ph~e~ ~ 5-Gilx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Prod 25-Ser-Leu-Pro-Ser-Pro~ 30-Ser-Arg-Leu-Pro-Gly~ 35-Pro-Pro-Asx-Thr-Pro140-IIe-Leu-Pro-Glx-Ser'145_Leu-Pro wherein Asx is Asp and Glx is Gln, and wherein the peptide sequence also includes at least one terminal Lys residue. I=urthermore, peptide sequences and variant sequences of less than 23 amino acid residues can be used.
The anti-hCG antibodies produced in accordance with the present invention can be used advantageously in as:,ays, as more fully described herein.
~o DETAILED DI=SCRIPTION OF THE INVENTION
The present invention providles a method far purifying anti-hCG antibodies using hCG
1 5 analyte-analogs. The claimed method enables the production of a purified polyclonal anti-hCG antibody having a specificity comparable to that of a monoclonal anti-hCG
antibody. The method of the invention is highly advantageous in terms of time savings and lower production costs by comparison to the conventional method described above.
The following terms used herein have the following meanings:
2 0 The term "determin;ints" refers to those regions of the analyte or other specific binding member which are intimately involved in specific binding reactions which are typified by the immunoreactive binding of antigens and antibodies. In essence, it is the determinants which differentiate antigens, and therefore, antibodies from one another on the basis of immunological specificity.
2 5 The term "analyte-analog" refers to a molecule which has substantially the same spatial and polar organization as one or more determinants of the analyte of interest. This duplication of the determinants) enables the analyte-analog to mimic the specific binding characteristics of the analyle. Therefore, the analyte-analog can bind to an analyte-specific binding member. In addition, the analyte-analog can be modified such that while it is not 3 0 identical to the analyte it includes the necessary determinants) for binding to the analyte-specific binding member.
The term "specific binding member" refers to a member of a specific binding pair, i.e., two different molecules wherein one of the molecules through chemical or physical means specifically binds to the second molecule. Immunoreactive specific binding members 3 5 include antigens, haptens, anfibodies~, and complexes thereof including those formed by recombinant DNA methods or peptide synthesis. An antibody can be a monoclonal or polyclonal antibody, a recombinant protein or a mixtures) or fragments) thereof, as well as a mixture of an antibody .and other specific binding members. The details of the preparation of such antibodies and their suitability for use as specific binding members are welt known to those skilled in the art.
The term "label" refers to any substance which is attached to a specific binding member and which is capable of producing a signal that is detectable by visual or instrumental means. Various suitable labels for use in the present invention can include chromogens; catalysts; fluorescent a~mpounds; chemiluminescent compounds;
radioactive labels; direct visual labels including colloidal metallic and non-metallic particles, dye 1 0 particles, enzymes or substrates, or organic polymer latex particles;
liposomes or other vesicles containing signal pr~~ducing ;substances: and the like.
A large number of enzymes suitable for use as labels are disclosed in U.S.
Patent No.
4,275,149, columns t9-23. Also, an example of an enzyme~substrate signal producing system useful in the present invention is the enzyme 1 5 alkaline phosphatase and the substrate vitro blue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate or a derivative or ;analog thereof.
In an alternative signal producing system, the label can be a fluorescent compound where no enzymatic manipulation of the label is required to produce a detectable signal.
Fluorescent molecules such as fluorescein, phycobiliprotein, rhodamine and their 2 0 derivatives and analogs are suitable for use as labels in this reaction.
A visually detectable, colored particle can be used as the label component of the indicator reagent, thereby providing llor a direct colored readout of the presence or concentration of the analyte in the sample without the need for further signal producing reagents. Materials for use as the cc>lored particles are colloidal metals, such as gold, and 2 5 dye particles as disclosed in U.S. Pat. Nos. 4,313,734 and 4,373,932.
The term "indicator rE~agent" refers to a label attached to a specific binding member.
The indicator reagent produa~s a detectable signal at a level relative to the amount of an analyte in the test sample. Generally, the indicator reagent is detected or measured after it is captured on a solid phase material, but unbound indicator reagent can also be measured to 30 determine the result of an assay.

P

The specific binding member of the indicator reagent is capable of binding either to the analyte as in a sandwich assay, to the capture reagent as in a competitive assay, or to an ancillary specific binding member as. in an indirect assay. The label, as described above, enables the indicator reagent to produce a detectable signal that is related to the amount of analyte in the test sample. The specific binding member component of the indicator reagent enables the indirect binding of the label to the analyte, to an ancillary specific binding member or to the capture reagent. The selection of a particular label is not critical, but the label will be capable of generating a detectable signal either by itself, such as a visually detectable signal generated by colored organic polymer latex particles, or in conjunction 1 0 with one or more additional signal producing companents, such as an enzyme/substrate signal producing system. ~~ variety of different indicator reagents can be formed by varying either the label or the specific binding member; it will be appreciated by one skilled in the art that the choice involves c:onsider2~tion of the analyte to be detected and the desired means of detection.
1 5 The term "capture reagent" refers to an unlabeled specific binding member which is usually, but not in every case, attached to a solid phase. The attachment of the components is essentially irreversible and can include covalent mechanisms. The capture reagent is used to facilitate the observation of the detectable signal by substantially separating the analyte and/or the indicator reagent from other assay reagents and the remaining test sample. The 2 0 specific binding member of the capture reagent can be specific either for the analyte as in a sandwich assay, for the indicator reagent or analyte as in a competitive assay, or for an ancillary specific binding member which itself is specific for the analyte, as in an indirect assay.
The term "ancillary specific (binding member" refers to any member of a specific 2 5 binding pair which is used in the as:>ay in addition to the specific binding members of the capture reagent and the inclicator reagent. For example, in an indirect assay an ancillary specific binding member may bind the analyte as well as a second specific binding member to which the analyte itself cannot attach, or in an inhibition assay the ancillary specific binding member may be a reference binding member, as described below. One or more 3 0 ancillary specific binding members can be used in an assay.
The term "solid phase" refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. ,An assay device of the present invention can have many configurations, several of which are dependent upon the material chosen as the solid phase.
For example, the solid phase can include any suitable porous material. By "porous" is 3 5 meant that the material is one through which liquids can flow and can easily pass. In the present invention, the solid iphase can include a fiberglass, cellulose, or nylon pad for use in a pour and flow-through assay device having one or more layers containing one or more of the assay reagents; a dipsnick for a dip and read assay; a test strip for wicking (e.g., paper) or thin layer chromatographic (e.g., nitrocellulose) techniques; or other porous material well known to those skilled in the art. The solid phase, however, is not limited to porous materials. The solid phase can also comprise polymeric or glass beads, microparticles, tubes, sheets, plates, slides, wells, tapes, test tubes, or the like, or any other material which has an intrinsic charl~e or which can retain a charged substance.
The following abbrs~viations are used in the description of the invention:
Abbreviation~ Acid AbbreviationAmino Acid ~1r ~ Name Ala Alanine Ile Isoleucine Arg Arginine Leu Leucine Asn Asparagine Lys Lysine Asp Aspartic Acid Met Methionine (Aspartate) Asx Aspartic Acid Phe Phenylalanin or Asparagine a Cys Cysteine Pro Proline Gln Glutamine Ser Serine Glu Glutamic Acid Thr Threonine (Glutamate) Glx Glutamine or Trp Trytophan Glutamic Acid Gly Glycin~e Ty r Tyrosine His Histidine Val Valine Xaa Unknown or other General Methods and Materi~l,~
synthetic Pe ties The present invention includes chemically synthesized CTP fragments, i.e., analyte-1 5 analogs, for the purification of anti-hCG antibodies. In a preferred embodiment, such a fragment comprises the following amino acid sequence:

Asp112-Pro-Arg-Phe115_Gln-Asp-Ser-Ser-Ser120_Ser-Lys-Ala-Pro-Pro125_ Pro-Ser- Leu-Pro-SE~r 130-Pro-Ser-Arg-Le u-Pro 135-Gly_ pro-Ser-Asp-Thr140-Pro-Ile-Leu-Pro-GIn145, Such a sequence is described by Morgan et al., Mol. Cell. Biochem. 2(1 ), 97-99 (1973) The inclusion of the 112-122 peptide region in a synthesized fragment of the present invention has been found to provide at least one, and possibly three, additional determinants which further and advantageously distinguish this hCG analyte-analoc_I from other glycoproteins or other CTP
peptide 1 0 sequences. Furthermore, in a further preferred embodiment an analyte-analog of the present invention can include one or more Lys residues at either end of the sequence. It has been found that the addition of the Lys residues facilitates the insolubilization of the peptide for the performance of column chromatography. For example, in accordance with the invention a peptide sequence, containing the CTP 112-145 analyte-analog was synthesized 1 5 with five additional lysine residues and coupled to a resin support to form an affinity column for purifying anti-hC;G antibodies. The addition of the polylysine unit on the COOH
terminus of the CTP analyte-analog was found to aid the coupling of the analyte-analog to the support (e.g., Affigel~t 0) in an affinity column without adversely affecting antibody performance (72-78% coupling efficiency).
2 0 In still another emt~odiment, an analyte-analog provided by the instant invention camprises a variant of the (:TP sequence, modified as follows:
Asx112-Pro-Arg-Ph~~115_Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly 135-Pro-Pro-Asx-Thr-Pro1 40-2 5 Ile-Leu-Pro-Glx-Ser ~ 45-Leu-Pro.
Such a sequence was described by l3ahl et al., Biochemical and Biophysical Research Communications, 48(2), 416-422 .(1972) .
This CTP variant differs from the first embodiment described above in 3 0 being modified such that one Ser amino acid residue is deleted from the 120 position, a Pro replaces a Ser at the 138 position, and a -Ser-Leu-Pro grouping is added to the sequence.
In a further preferred embodiment, ~4sx is Asp, Glx is Gln and the analyte-analog includes the addition of one or more Lys residues at either end of the sequence.
The synthesis of peptide sequence determinants by peptide generation or other 3 5 chemical processes are not the only ways the present invention can be practiced.
Alternative methods may be more advantageous to the individual practitioner based upon his 1341p14 or her expertise, the mate~~ials available, and the type of determinant to be duplicated. For example, recombinant DNA techniques can be employed to reconstruct the determinant necessary for binding.
Alternatively, the n~scessary analyze-analog determinants can be produced by "mincing" or "digesting" the analyte into smaller pieces or fragments. Such fragments can be made, for example, by rnechanical means such as sonication, by chemical means or by enzymatic means. The resultant fragmented analyze material can be passed through an affinity chromatography column in which is immobilized an appropriate antibody to which the antigenic determinants can attach. Thereafter, the analyze-analogs can be eluted from 1 0 the column with suitable solvents.
Antibodies were prepared by eliciting a response in goats to an immunogen. The immunogens were adminis?,ered to the animals by a series of inoculations, in a manner well 1 5 known to those skilled in the art, and it should be understood that although goats were the immune hosts used in the experiments detailed herein, any in vivo or in vitro host capable of producing antibodies to the immun~ogens can be used. The anti-hCG
antibodies can be elicited by using whole molecule hCG as the immunogen or by using an hCG
analyte-analog, such as a synthetic f3-subunit or a C-terminus peptide sequence of the present invention as 2 0 the immunogen.
The antibodies which were generated against the f3-subunit of the hCG
molecule, were then passed through ~~n affinity column in which either a CTP peptide or a CTP variant of the present invention was immobilized. After washing the column, the antibodies specific for the CTP determinants were eluted from the column. These polyclonal antibodies 2 5 produced in accordance with the invention were found to have negligible cross-reactivity with hLH and can be advantageously used in immunoassays, such as heterogeneous sandwich immunoassays for the dete~~tion of vvhole molecule hCG, by comparison with conventionally produced antibodies. In us~s, the re;>ultant purified antibodies can be coupled to an appropriate functional moiety, for example a label or a solid phase, to produce an indicator 3 0 reagent or capture reagent for use in the immunoassay. The exact conditions of use will be determined by the routineer based upon the type of individual assay and its unique requirements.
It has been found that the use of the preferred CTP variant of the invention enables the production of a very rE~producit>le single-step affinity column chromatography 3 5 procedure for the purification of highly specific polyclonal antibodies which recognize the t3-subunit of the hCG analyte but which do not react with hLH, thereby enhancing the 1340'4 specificity of an assay when such antibodies are used therein. Additionally, the potyclonal antibodies purified using the CTP variant of the invention have been found to increase assay sensitivity by comparison with use of the CTP peptide.
Other advantages of the present invention include the ease with which a peptide affinity column can be preF~ared using the analyte-analog and the ease with which specific antibodies can be generated using such a ootumn in comparison to conventional methods.
Thus, an affinity column can be produced according to the present invention which eliminates the need for the dual whole-molecule hCG and hLH affinity columns of the prior art, and such a column has been found to produce an antibody pool showing virtually no t 0 cross-reactivity to hLH. Furthermore, the process is rapid, reliable, reproducible and cost effective. In addition, poly~:lonal antibodies purified according to the present invention have been found to posses specificities approaching those observed with conventionally used monoclonal anti-hCG antibodies. This surprising result can be attributed to the limited number of epitopes present on the CTP (Bidart et al., J. Immuno. 134: 457, The analyze-analogs provided by the present invention can also be used to produce immunogens for eliciting antibodies specific for the analyte-analog determinant(s). Such immunogens have been made by coupling the analyze-analog to a carrier protein such as hemocyanin or bovine serum albumin (BSA). For example, such an immunogen can include 2 0 a carrier protein coupled to the f3-subunit of hCG ar a carrier protein coupled to the CTP
sequence or a portion or variant thereof. The peptide and the carrier can be linked by a variety of linking groups in~~luding carbamate, amido, amino, ihioether or ether.
The following Examples describe in detail preferred embodiments of the present invention, and are intended to be illustrative rather than limitative thereof.
EXAMPLES
Example t 3 0 ~'betis of a heroes oeotide A herpes peptide analyte-analog was produced in accordance with the present invention, corresponding to amino acids 290-300 of herpes simplex virus type I
glycoprotein D (HSIGD) encoded in the region between base pairs t 108-1140 (Watson, R.
3 5 J. et. al., Science, ~$: 381-384 (t 982), as follows. The peptide sequence for the analyte-analog is shown below:
t t0 Gln-Pro-Glu-Leu-Ala-Pro-Glu-Asp-Pro-Glu-Asp-Gly The amino acid glycine was linked at the C-terminus of the peptide to act as a linker between the peptide and resin support.
Boc-Gly-OCH2-Pann resin Hras synthesized according to the following procedure described in Mitchell, A. R. et. al., ,,I. Org. Chem., ~: 2845-3852 (1978) and Mitchell, A.
R. et. al., J. Am. Chem. ~~"~,$: 7357-7362 (1976). Aminomethyl-resin (2.36 g, 0.25 mmol/g) was placed in a rE~action vessel and allowed to swell in methylene chloride 1 0 (CH2C12) for 30 minutes. It was then coupled to Boc-Gly-OCH2 C6H4CH2C02H
(0.89 mmol) in methylene chloride by the addition of dicyclohexylcarbodiimide (DCC, 0.89 mmol).
Protected amino acids were coupled to the resin support in a stepwise manner by preformed symmetric anhy~~ride chemistry, except in cases of aspartic acid, and glutamine.
1 5 All amino-terminal residues were protected by t-butyloxy carbonyl (t-BOC) and side chains of various amino acid residues were protected by the following groups:
Asp by cyclohexyl (OChxI) and Glu by bent yl (OBzI). The following coupling protocol was used for amino acids Glu, Pro, Leu, Ala.
1 ) CH2C12 was added, shaken for one minute and filtered (the process was repeated 2 0 six times, i.e., 6x1 minulle);
2 ) 50% trifluoroacetic acid (TFA)/CH2C12, 1 x1 minute;
3 ) 50% TFA/CH2C12, 1x20 minutes;
4 ) CH2C12, 6x1 minute;
5 ) 5% diethylamine (DIEA)/CH2C12, 2x2 minutes;
2 5 6 ) CH2C12, 3x1 minutes; and 7 ) protected amino acid, eight equivalents, was dissolved in methylene chloride and cooled to 0 °C. 1'o this solution, N-N-dicyclohexylcarbodiimide (DCC) was added (four equivalents in methylene chloride). After stirring for ten minutes at 0 °C, the solution was filtered. A final concentration of this symmetric anhydride 3 0 00.05 M to 0.1 NI) was added to the reaction vessel containing the resin.
The vessel was shaken for two hours at room temperature and filtered.
8 ) CH2C12, 3x1 minute;
9 ) 5% DIEAlCH2Cl~~, 1x2 minutes; and 1 0 ) CH2C12, 3x1 minute; and then 35 1 1 ) either step 7 was repeated or 1-hydroxybenzotriazole (HOST four equivalents) was dissolved in dimethylformamide (DMF) and cooled to 0 °C. To this solution, DCC (four equivalents) in CH2C12 was added followed by the addition of protected amino acid (four equivalents) in DMF:CH2C12 (1:1 ). This reaction mixture was stirred at 0 °C for ten minutes. Then the reaction mixture was transferred to the reaction vessel containing resin and shaken for two hours at room temperature.
1 2) CH2C12:DMF (1:'I), 3x1 nninute; and 1 3 ) CH2C12, 3x1 minute.
The completeness of the reaction was monitored by a quantitative ninhydrin test as described by Sarin, V.K. sit. al., analytical Biochemistry, ~: 147-157 (1981 ).
For protected amino acid Asp, steps 1 to 6 were the same as described above and 1 0 followed by:
7 ) protected amino acid (four equivalents) in methylene chloride was added to the reaction vessel with DCC (four equivalents) in methylene chloride and shaken at room temperature for 24-72 hours; and 8 ) CH2C12, 6x1 minute.
1 5 The completeness of the reaction was monitored by quantitative ninhydrin analysis.
For glutamine, a DC~~/HOBT coupling protocol was used as described by Konig and Geiger, Chem. Ber.,,~: 788-798 (1970).
The fully protected peptide-resin (1 g) was allowed to swell in methylene chloride for five minutes and the N-alpha-BOC protecting group was removed using the following 2 0 protocol:
1 ) CH2C12, 6x1 minute;

2 ) 50% TFA/CH2C1~,, 1x1 minute;

3 ) 50% TFA/CH2C1;~, 1x20 iminutes;

4 ) CH2C12, 6x1 minute;

25 5 ) 5% DIEA/CH2C1~~, 1x3 minutes;

6 ) CH2C12, 4x1 minute; and 7 ) the resin was then dried.

The peptide-resin was divided into two separate reaction vessels and treated for 60 3 0 minutes at 0 °C with anhydrous hydrofluoric acid (13.5 ml) to which p-cresol (1.5 ml) had been added. The hydrofluoric acid was distilled-off in vacuo at 0 °C. The cleaved free peptide and resin were washed four times with diethyl ether (10 mI aliquots), and the peptide was extracted with three extractions each of 10% and 20% aqueous acetic acid respectively. The aqueous ~extractions were combined and washed three times each with 10 3 5 milliliter aliquots of diethyl ether and ethylacetate. The aqueous layer was then lyophilized to provide a white fluffy peptide. The polypeptide was purified by reversed-phase high performance liquid chromatography (HPLC) according to routine protocols such as that described by Rivier, et ail., Journal of Chromatography, 288; 303-328 (1984) .
'The composition of the purified peptide was confirmed by hydrolysis in 6 N hydrochloric acid (HCI) in vacuo at t 10 °C for 24 hours and was subsequently analyzed on an amino acid analyzer.
Example 2 y~ynthesis of ti-hCG C-terminus v ~tid ~
1 0 An hCG analyze-analog, corresponding to CTP 112-145 of f3-hCG, was produced in accordance with the present invention as follows. The peptide sequence is shown below:
Aspt 12-Pro-Arg-Phn115-Gln-Asp-Ser-Ser-Ser120.Ser-Lys-Ala-Pro-Pro125-Pro-Ser-Leu-Pro-Ser130-Pno-Ser-Arg-Leu-Pro135-Gly-Pro-Ser-Asp-Thr~ 40-Pro-Ile-Leu-Pro-GIn~145 The analyze-analog was synthesized on a resin support by stepwise solid phase synthesis starting with the carboxy-terminal residue. Substantially, the procedure described in Barany and M~errifield. The Pe~ti, des, 2: 1984, Gross, E. and Meinehofer, J.
2 0 eds, Academic Press, New York, N.. Y. (1980) was used for this synthesis.
A BOC-L-Gln-OCH2-resin was transterre~d to a reaction vessel of a Beckman synthesizer, Model 900.
Protected amino acids were' coupled in a stepwise manner to the resin support substantially in accordance with the chemistry described in Example 1. Amino acid, Leu, at positions 128 and 134, were double coupled to ensure completeness of the coupling reaction.
After 2 5 incorporation of Pro at position 126, all subsequent amino acids were double coupled.
The completed peptide was cleaved oft the fully protected peptide-resin with anhydrous hydrofluoric acid using the protocol described in Example 1. The crude peptide was purified using reversed-phase I~PLC on a C4 column (10 mm x 25 cm) using a flow rate of three mUmin and employing gradients of 0.1% TFA/H20 (A) and 100%
acetonitrile 3 0 (B) as the solvent systems. The gradient used was 10% B to 35% B over a thirty minute period.
The polypeptide elution from the HPLC column was monitored at 225 nm and 280 nm. The composition of the purified peptide was confirmed as described in Example 1.

Example 3 ~ynthsrsis of fi~~h ooly[ysine C-termims off, typ 'des A polylysine analyte-analog, including five additional lysine residues attached to the C-terminus, referred to as polylysine CTP, was produced in accordance with the invention using the following procedure. The additional lysines facilitated the production of a peptide immunosorbent for use in an affinity column to purify anti-hCG antibody. The additional amino acids) can be added to either end of the peptide sequence, for example:
Asp112-Pro-Arg-Phe115_Gln-Asp-Ser-Ser-Ser120_Ser-Lys-Ala-Pro-Pro125_ Pro-Ser-Leu-Pro-Ser130-Pro-Ser-Arg-Leu-Pro135_Gly_pro-Ser-Asp-Thr~ 40-Pro-Ile-Leu-Pro-Gln ~ 45-Lys;-Lys-Lys-Lys-Lys The peptide was as;~embled, cleaved and purified as described above except that it was 1 5 synthesized on an Applied Biosystems synthesizer, Model 430A. A Boc-L-Lys (2 CI-Z)-OCH2-Pam-resin was tran:;ferred to a reaction vessel, and protected amino acids were coupled in a stepwise manner to the resin support by preformed symmetric anhydride chemistry (except in the case of arginine and glutamine addition where DCC/HOBT coupling protocol was used.) The fully protected peptide-resin was treated with anhydrous 2 0 hydrofluoric acid followed by extraction and purification of the peptide as described above.
Example 4 Synthesis of a polylysine CTP variant 2 5 A polylysine CTP variant analyte-analog, according to the invention was synthesized having the following sequence:
Asx112-Pro-Arg-Phn115_G~~,x-Asx-Ser-Ser-Ser120_Lys-Ala-Pro-Pro-Pro125_ Ser-Leu-Pro-Ser-Pro130-S~er-Arg-Leu-Pro-GIy135-Pro-Pro-Asx-Thr-Pro140_ 3 0 Ile-Leu-Pro-Glx-Ser'145-Leu-Pro wherein Asx is Asp, Glx is Gln and five additional Lys residues are included on the end of the sequence. The peptide was assembled, cleaved and purified substantially in accordance with the procedure described in Example 3, except the side chain functional groups of the amino 3 5 acids were protected by coupling reactions as follow: Lys and 2-CI-Z; Ser and Bzl; Asp and OBzI; Arg and tosyl (TOS) ; and Thr and Bzl. Amino acids at positions 112, 123, 124, 127, 133, 135, 136, 141, 142 and 146 were recoupled using symmetric anhydride chemistry in methylene chloride substantially in accordance with the procedure described in Example 1.
The fully protected peptide-resin was treated with anhydrous hydrofluoric acid followed by extraction of th~~ peptide, substantially in accordance with the procedure described in Example 1, except that two additional 40% aqueous acetic acid extractions were performed. The crude peptide was then purified by reversed-phase HPLC on a C4 column (Vydac 22 x 250 mm; The ;>eparation Group, Hesperia, CA), substantially in accordance with the procedure described in Example 1, using a flow rate of 12 ml/min and employing 1 0 gradients of 0.1% TFA/H2C) (A) and 100% acetonitrile (B) as the solvent systems. The gradient was started at 19°i~ B, where it was maintained for three minutes and then increased to 40% B over a twenty minute period using curve number seven of Water's automated gradient controller (Water's Millipore Corporation, Bedford, MA).
The gradient was maintained at 40% B for one minute and then brought back to 19% B over a one minute 1 5 period. The polypeptide elution from the HPLC column was monitored at 225 nm and 254 nm simultaneously. The composition of the purified peptide was confirmed by amino acid analysis as described in Example 1.
Example 5 2 0 ~':hemo,~yanin immuno9en The CTP produced substantially in accordance with the procedure described in Example 2 was coupled to hemocyauin (from Limulus Polyphemus Hemolymph type VIII;
Sigma, St. Louis, MO) by a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 2 5 method. One milligram of C;TP was dissolved in phosphate buffered saline (1.0 ml).
Hemocyanin (2.0 mg) was weighed and transferred to the CTP solution. Twenty milligrams of EDC was measured and dissolvecl in water (200 ~I). The EDC solution was then slowly added to the CTP-hemocyanin solution while mixing. The mixture was reacted for one hour and was then dialyzed against water in a cellulose dialyzing tube (Spectra/por~, Spectrum 3 0 Medical Industries, Inc., Los Angeles, CA; mw 12,000-14,000). The dialysis occurred over 24 hours with three volume changes. After dialysis, the solution was clarified by centrifugation. The resulting conjugate was assayed by Biuret assay for protein content.
~ "~R ~ d ~ o..,. a n, t~

Example 6 ~CG Antibody Purification An affinity column for antibody purification was made using an analyte-analog of the present invention, according to the hollowing procedure. The HPLC-purified polylysine CTP
variant peptide (made substantially in accordance with the procedure described in Example 4) was dissolved in 0.1 M 3-(N-morpholino)-propanesulfonic acid (MOPS) buffer, pH
7.5. The resulting solution was then combined with a slurry of Aftigel-10 resin (Bio-Rad, Richmond, CA) that had previously been washed and activated in 0.1 M MOPS, pH
7.5. The 1 0 ratio of peptide (mg) to Affigel-10 (ml) was approximately 7:1. After coupling overnight at 2-8°C, the peptide coupled resin vvas washed three times with 0.1 M
MOPS, pH 7.5, and then was equilibrated in 'iris-saline buffer containing 0.1 M tris-(hydroxy-methyl)-aminomethane (pH 7.5), 0.5 M NaCI and 0.1% NaN3, and an initial absorbance at the wavelength of 280 nanometers (A2go) was determined.
1 5 Anti-serum raised in goats against the f3-subunit of hCG was precipitated with ammonia sulfate at 2-8°C. The precipitated antibody was recovered by centrifugation, and the pellet was resuspended in Tris-saline buffer. The resuspended antibody was exhaustively dialysed against the Tris-saline buffer at 2-8°C and was then stored at -15°C.
Column chromatography purification of the antibody was performed at room 2 0 temperature. The frozen antibody was thawed and was allowed to equilibrate to room temperature. The antibody was pas;>ed over the affinity column at a flow rate of 1.5 milliliters/minute. Unbound material was removed by washing the calumn with the Tris-saline buffer until the initial A2gp baseline was re-established. The bound antibody was eluted in a 0.1 M glycine-HCI (pH 2.5) bufter at a flow rate of 1.5 milliliterslminute. The 2 5 antibody containing traction;; were pooled and immediately neutralized with 0.5 M Tris. The neutralized antibody solution was exhaustively dialysed against 0.02 M sodium phosphate, pH 7.2, 0.15 M NaCI at 2-8 °C. The dialysed antibady solution was then concentrated to approximately 10 milligrarris/milliliter and was stored at -15°C.
3 0 comparison of Purified Antibodies Equivalent protein masses of CTP peptide purified antibody and CTP variant purified antibody, produced substantially in accordance with the procedure described in Example 6, were used to demonstrate the performance of the antibodies produced using the principles of the present invention. To accomplish the foregoing, the CTP peptide antibody and the CTP
3 5 variant antibody were conjuctated to alkaline phosphatase, as described below, to form two * Trade~k 1~41~14 different antibody/enzyme indicator reagents for use in a heterogeneous sandwich immunoassay.
Oxidation of the alkaline phosphatase was performed in 25 mM sodium periodate, 0.2 mM sodium acetate, and 0.2 M sodiium phosphate, pH 4.5, for three hours at room temperature in the dark. Ctxidation was terminated by by the addition of glycerol, and the resultant material was dialyzed overnight against 10 mM sodium acetate, pH
4.5, 100 mM
NaCI, 1 mM MgCl2 and 1 mM ZnCl2. The dialyzed alkaline phosphatase was combined with the respective purified antibodies at a 1:1 ratio with a final antibody concentration between 1.5 to 2.0 milligram/millilits~r. The pH of the solution was increased to pH
9.5 by the 1 0 addition of sodium bicarbonate, and the solution was allowed to incubate for five hours in the dark at room temperature. The respective indicator reagents were transferred to 2-8°C
and reduced by the addition of sodium sodium borohydride for three hours. The reduced indicator reagents were then dialy~:ed overnight at 2-8°C against 50 mM
Tris-HCI, pH 7.5, 0.1 mM MgCl2, 0.1 mM ZnCl2 and 0.1 % (w/v) NaN3.
1 5 The resulting indics~tor reagents were tittered to produce equivalent signals when used in an hCG sandwich innmunoassay which was performed on an Abbott IMxn automated microparticle enzyme immunoassay system (Abbatt Laboratories, Abbott Park, IL). The capture reagent was a monoclonal anti-f3-hCG antibody coated upon microparticles (in 50 mM Tris-HCI, pH 7.5, 0.5 mM NaCI, 0.1 % NaNg and 13.6% sucrose). The sample (50 ~I) 2 0 was mixed with the capture reagent (50 pl), one of the indicator reagents (50 pl; in 50 mM Tris-HCI, pH 7.4, O.Ei M NaCI, 2.25% (w/vJ fish gelatin, 1% (w/v) Brij-35, 1.0 mM
MgCl2, 0.1 mM ZnCl2 and 0.1% (w/vJ NaNg and 10 ~I (75/25 vNJ normal human serum/normal goat serum) and a diluent (10 p.l; 0.05 M Tris-HCI, at pH 7.5, containing 0.3 M NaCI and 0.1% sodium azide). The reaction mixture was dispensed into a reaction 2 5 well and was incubated for five minutes. An aliquot of the reaction mixture (1 t 0 pl) was transferred !o a glass fiber matrix to which the microparticles bind, and the matrix was washed with diluent. A fluorescent substrate, 4-methylumbelliferyl phosphate (65 pl) was added to the matrix and the sannple was read by a fluorometer. The rate of fluorescence emitted from the surface of the matrix was directly proportional to the concentration of 3 0 analyte in the sample.
Calibrators containing known amounts of hCG (in a normal calf serum matrix) were measured and used to calculate a standard curve for each of the indicator reagents. The calibration results are presented in Table 1. An indicator reagent titer of 1/2000 was used for the reagent containing the CTP variant antibody as the specific binding member, and an 3 5 indicator reagent titer of 1 /t 000 wa;s used for the reagent containing the CTP peptide antibody as the specific binding mernber. As shown in Tabie 1, the indicator reagent made f~
* Trade-mark from the CTP variant antitbdy provided a higher signaUnoise (SIN) ratio by producing a lower background at zero rnlU/ml of hCG. The rate or counts/second/second (ds/s) is a measurement of the intensity of the fluorescent emission produced by the enzyme/substrate reaction (described by Fiore et al., Clinical Chemistry, 34 (9); 1726-1732, The SIN is defined as the measured rate for each sample divided by the measured rate for the zero calibrator.
Table 1 Comparison of Indicator Reagent Performance ~' P~eotide Antibody CTP Variant PeRtide Antibody Calibrators Rates SIN Rates SIN
mlU/ml of hCG c/sls c/s/s 0 4.5. - 2.4 -1 0 22.0 4.9 29.5 12.1 7 5 157.1 35.3 204.8 83.9 250 576.2' 129.5 708.2 290.3 500 1099.6. 247.1 1114.9 456.9 1000 2080.1 467.4 2016.9 826.6 A set of controls wars also tested, and the results are presented in Table 2 as determined from the stand~3rd curves produced by the calibrators. The controls contained approximately 25, 150 or 750 mlU/ml of hCG. The results demonstrated that the two 1 5 different indicator reagents, both made from antibodies purified according to the present invention, produced equivalent signals, but that a much lower concentration of the indicator reagent containing the CTF~ variant antibody (a two fold lower concentration) was needed to produce the signal.

~34~Q~4., Table 2 Measurement of Controls with Standard Curve ~' Peptide Antibody CTP Variant Pectide Antibody Controls mIU/ml of hCG mIU/ml of hCG
mIU/ml of hCG from standard curve from standard curve 2 5 22.7 23.0 1 50 142.9 143.7 750 756.5 766.2 Sensitivity (by 2 0.4 0.2 standard deviations) The assay results also dernonstratErd that the indicator reagent made from a preferred antibody produced according to the present invention, that is purified using the CTP variant, provided an increase in assay sen:>itivity as defined as the 95% confidence limit at zero mIU/milliliter hCG
1 0 In addition, hLH cross-reactivity was determined by performing the same assay using known hLH test samples and measuring the resultant hCG values. The hLH
cross-reactivity was found to be 3 to 8 tinnes lower when the CTP variant antibody was used in the indicator reagent, as demonstrated by the results presented in Table 3.

~341p'4 Table 3 Cross-reactivity hLH Test Samples ~.If' Peptide Antibody CTP Variant PQOtide Antibod,K
mlUlml rnlU/ml of hCG mIU/ml of hCG
from standard curve from standard curve 500 0.48 0.06 1000 0.98 0.30 It will be appreciated by one skilled in the art that many of the concepts of the present invention are equally applicable to the production of analyte-analogs and the purification of antibodies far analytes other than hCG. Accordingly, the preferred embodiments described an~j the alternative embodiments presented are intended as examples rather than as limitations. Thus, this description of the invention is not intended to limit 1 0 the invention to the particular embodiments disclosed, but it is intended to encompass all equivalents and subject matter within the spirit and scope of the invention as described above and as set forth in the following claims.

Claims (12)

1. A method for purifying an anti-hCG antibody, comprising the steps of:
a contacting a body fluid containing an anti-hCG antibody with an hCG analyte-analog insolubilized on a support, wherein said hCG analyte-analog is a peptide sequence comprising:
Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-pro-Ser-Pro130-Ser-Arg-Leu-Pro-G1y135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro whereby anti-hCG antibody specific for said peptide sequence is absorbed; and b. eluting said anti-hCG antibody thus specifically absorbed.

2. The method according to Claim 1, wherein wherein Asx is Asp and Glx is Gln.

3. The method according to Claims 1 or 2, wherein said peptide sequence further comprises at least one terminal Lys residue.

4. The method according to Claim 1, wherein said peptide sequence comprises:
Lys-Lys-Lys-Lys-Lys-Asx112-pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro.

5. The method according to Claim 1, wherein said peptide sequence comprises:
Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro-Lys-Lys-Lys-Lys-Lys.

6. An hCG analyte-analog peptide, having the sequence comprising:
Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro wherein Asx is Asp and Glx is Gln, and wherein said peptide sequence further comprises at least one terminal Lys residue.

7. The peptide according to Claim 6, having the sequence comprising:
Lys-Lys-Lys-Lys-Lys-Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro.

8. The peptide according to Claim 6, having the sequence comprising:
Asx112-Pro-Arg-Phe115-Glx-Asx-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asx-Thr-Pro140-Ile-Leu-Pro-Glx-Ser145-Leu-Pro-Lys-Lys-Lys-Lys-Lys.

9. An antibody produced according to a method for purifying an anti-hCG
antibody, comprising the steps of:
a. contacting a body fluid containing an anti-hCG antibody with an hCG analyte-analog insolubilized on a support, wherein said hCG analyte-analog is a peptide sequence comprising:
Asp112-Pro-Arg-Phe115-Gln-Asp-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Pro125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asp-Thr-Pro140-Ile-Leu-Pro-Gln-Ser145-Leu-Pro whereby anti-hCG antibody specific for said peptide sequence is absorbed; and b. eluting said anti-hCG antibody thus specifically absorbed.

10. The antibody according to Claim 9, wherein said peptide sequence further comprises at least one terminal Lys residue to attach said sequence to said support.

11. An affinity column for purifying anti-hCG antibodies, comprising:
a an hCG analyte-analog peptide having the sequence comprising Asp112-Pro-Arg-Phe115-Gln-Asp-Ser-Ser-Ser120-Lys-Ala-Pro-Pro-Prod125-Ser-Leu-Pro-Ser-Pro130-Ser-Arg-Leu-Pro-Gly135-Pro-Pro-Asp-Thr-Pro140-Ile-Leu-Pro-Gln-Ser145-Leu-Pro wherein said peptide is immobilized upon b. a support.

12. The affinity column according to Claim 11, wherein said peptide sequence further comprises at least one terminal Lys residue to attach said sequence to said support.